At present, hepatitis C is a curable disease, and the application of alpha-interferon combined with ribavirin can make more than 90-95% of patients achieve complete cure, and, as long as the drug dose and the course of treatment are sufficient, there is basically no recurrence. There are many patients with hepatitis C treated at my clinic, and so far, only one case of cirrhosis among my patients has relapsed 3 months after clinical cure, and the relapse was mainly due to the inadequate dose of alpha-interferon (reduced due to platelet drop below 50,000) and the decrease of her own immune control ability. Although the above mentioned therapies can enable the majority of patients to achieve recovery, there is a small group of patients who may be in the middle or late stages of hepatitis cirrhosis, or who have other systemic diseases, such as HIV, renal insufficiency, hematologic diseases, etc., which do not facilitate the use of alpha-interferon, or who cannot tolerate the side effects of alpha-interferon, and such patients can only be treated with symptomatic regimens in the past, but the results will be The progression of hepatitis C is more advanced than that of hepatitis C. The development of hepatitis C is much faster than that of hepatitis B, and cirrhosis can be formed in about 10 years, and some of them will be converted to liver cancer. Moreover, if antiviral treatment is not given before liver transplantation to clear the virus, the transplanted liver will be infected with hepatitis C virus soon after transplantation, which may result in transplantation failure and financial failure. Therefore, for hepatitis C, timely antiviral treatment therapy is even more important. Recently, the world’s medical treasury has brought another boon to patients who are not comfortable with the use of alpha-interferon, with the availability of new drugs – namely, numerous new drugs developed in the United States and Europe. These new drugs include NS3/4A protease inhibitors in the hepatitis C virus genome (Simeprevir, etc.); NS5B polymerase nucleoside analogue inhibitors (Soforsbuvir-Sofibrium); NS5A inhibitors (Dclatasvir-Dacotaxel); and combinations of two or three drugs together such as: NS5B polymerase nucleoside analog inhibitor + NS5A protein inhibitor (two drugs taken together, only 1 tablet); NS3/4 protease inhibitor + NS5A inhibitor + CYP3A4 potent inhibitor, three drugs taken together, a total of 2 tablets. The most commonly used of these are sofosbuvir and daclatasvir, but both new drugs are currently very expensive. In China, due to the WTO accession to the relevant national laws – new drug drug patent protection period restrictions, therefore, there are no generic drugs available in China. I. Treatment options: (a) primary treatment or alpha-interferon treated without cirrhosis: either type 1a, 1b, 2, 3, 4, 5, 6 are applied for 12 weeks using combination of sofosbuvir (a generation drug) and daclatasvir (called second generation drug after the combination). Most of our patients belong to type 1b (refractory) and a very small proportion belong to type 2a (well-treated). (ii) Initial or alpha-interferon treated patients with compensated cirrhosis (child-pugh for grade A-early cirrhosis). The length of treatment is divided according to the area with or without ribavirin. 1, such as sofibuvir + daclatasvir and then + ribavirin, that is, the three drugs used together, the course of treatment is 12 weeks, but if it is well-treated, mainly genotype 2a, you can not add ribavirin, only the combination of sofibuvir and daclatasvir! 2, If you do not add ribavirin (some patients have serious side effects with ribavirin or cannot tolerate ribavirin) and use only the two drugs mentioned above, the course of treatment needs to be extended to 24 weeks. 3, so that it is entirely possible to avoid the use of alpha-interferon, in order to avoid the toxic side effects of interferon treatment, expand the indications for hepatitis C treatment, especially to give patients who have developed cirrhosis, especially in the middle and late stages of the disease to clear the virus, so that the disease stops further progress, or even reverses the opportunity. (iii) Patients with decompensated cirrhosis who are not waiting for liver transplantation (child-pugh is grade B or C) 1. ribavirin-resistant patients – sofosbuvir + daclatasvir + ribavirin, three-drug combination, 12-week course of treatment. 2.Ribavirin intolerant person – sofibuvir + daclatasvir combination, then the course of treatment needs to be extended to 24 weeks. (d) The cure rate of the above therapies is 95-99%, and the relapse rate is low. (v) If the economy does not allow the use, the following options are also available. 1, if due to economic problems can not afford to buy 2 generation products, you can also choose the following options: that is, a generation of sofibrium + interferon + ribavirin (for genotype 1 – refractory), a course of treatment for 12 weeks (cure rate of 80-90%, with recurrence). 2, not alpha with interferon, using sofibrium + ribavirin, a course of 24 weeks (for genotype 2 – the so-called good treatment type, China less), the same, the cure rate of 80-90%, there are relapses. Second, the adverse drug reactions: general weakness, dizziness, dry mouth, regurgitation (nausea), other: skin itching, dry cough, muscle aches. 50% appeared in the first week of taking the drug, after 7 days decreased significantly.